Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.54 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.44 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.44 |
| ▸ | MERTK | Q12866 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL92995 | 0.90 | CNR2 (0.52) | CNR2FAAHMAPTTHRBHPGD | |
| SCHEMBL8981479 | 0.88 | CNR2 (0.55) | CNR2FAAHMAPTTHRBHPGD | |
| SCHEMBL8981509 | 0.87 | CNR2 (0.53) | CNR2FAAHMAPTTHRBHPGD | |
| SCHEMBL13805556 | 0.87 | CNR2 (0.53) | CNR2FAAHMAPTTHRBHPGD | |
| SCHEMBL13805554 | 0.86 | CNR2 (0.52) | CNR2FAAHMAPTTHRBHPGD | |
| SCHEMBL8981574 | 0.86 | CNR2 (0.52) | CNR2FAAHMAPTTHRBHPGD | |
| SCHEMBL2187651 | 0.84 | LMNA (0.59) | CNR2MAPTTHRBHPGDRXFP1 | |
| SCHEMBL12697368 | 0.83 | FAAH (0.61) | CNR2FAAHMAPTHPGDGAA | |
| SCHEMBL12697309 | 0.80 | FAAH (0.57) | CNR2FAAHMAPTHPGDGAA | |
| SCHEMBL14536726 | 0.78 | CNR2 (0.53) | CNR2FAAHMAPTTHRBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1950212-B1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON HIV INTEGRASE | SHIONOGI & CO (JP) | 2016-02-24 | — | — | EP | disclosed |
| US-20120208998-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | YOSHIDA HIROSHI (JP) | 2012-08-16 | — | — | US | disclosed |
| US-8188271-B2 | Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-05-29 | — | — | US | disclosed |
| US-7858788-B2 | Bicyclic carbamoylpyridone derivative having HIV integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-7550463-B2 | Carbamoylpyridone derivatives having inhibitory activity against HIV integrase | SHIONOGI & CO., LTD. (JP) | 2009-06-23 | — | — | US | disclosed |
| US-20090143356-A1 | Polycylclic Carbamoylpyridone Derivative Having HIV Integrase Inhibitory Acitvity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| EP-1950212-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON HIV INTEGRASE | Shionogi Co., Ltd. (JP) | 2008-07-30 | — | — | EP | disclosed |
| US-20080161271-A1 | Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| EP-1852434-A1 | BICYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITING ACTIVITY | Shionogi Co., Ltd. (JP) | 2007-11-07 | — | — | EP | disclosed |
| US-20070249687-A1 | Carbamoylpyridone Derivatives Having Inhibitory Activity Against Hiv Integrase | SHIONOGI & CO., LTD. (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1790638-A1 | CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | Shionogi Co., Ltd. (JP) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161271-A1 | Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity | NR4A1, HAT1, NR4A2 | CNR2 1145/4885FAAH 3934/4885MAPT 4715/4885 |
| US-20120208998-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | CDKN1A, CDK2, CDK2AP1 | CNR2 3377/4885FAAH 3980/4885MAPT 2144/4885 |
| US-20090143356-A1 | Polycylclic Carbamoylpyridone Derivative Having HIV Integrase Inhibitory Acitvity | CDK20, CYP4A22, CDK10 | CNR2 501/4885FAAH 2767/4885MAPT 4110/4885 |
| US-20070249687-A1 | Carbamoylpyridone Derivatives Having Inhibitory Activity Against Hiv Integrase | CDKL4, CDKL5, CDKL1 | CNR2 1296/4885FAAH 3855/4885MAPT 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.